Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey

kocak, ozgur; kan, ozgur

doi:10.5578/flora.69026

Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey

Özgür KOÇAK, (Hitit Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Çorum, Türkiye)

Özgür KAN (Hitit Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Anabilim Dalı, Çorum, Türkiye)

Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi

6 1

Yıl: 2020 Cilt: 25 Sayı: 3 Sayfa Aralığı: 332 - 338 Metin Dili: İngilizce DOI: 10.5578/flora.69026 İndeks Tarihi: 15-10-2021

Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey

Öz:

Introduction: Toxoplasma gondii is an important parasite that can cause permanent sequelae to the fetus when infected during pregnancy in humans. Although the frequency of this parasite varies widely between countries, it is known that it is common in our country.The aim of this study was to determine the seroprevalence of toxoplasma in pregnant women admitted to a tertiary hospital in centralAnatolia and to evaluate the pregnancy outcomes together with seroprevalence.Materials and Methods: A total of 9311 patients admitted to a tertiary hospital between January 2016 and December 2018 wereincluded into the study. After serological examination, avidity test was performed in cases suggestive of acute infection. Amniocentesiswas recommended to be performed by Polimeraze Chain Reaction (PCR) in patients with low avidity.Results: The frequency of Toxoplasma immunoglobulin (Ig) G and M seropositivity rates were 20.3% and 0.28%, respectively. Lowavidity was found in approximately 27% of the patients with IgM positivity, and only 15.4% had low avidity by confirmatory test. Onepatient could not be reached during follow-up. PCR was performed in 4 patients whose low avidity value was confirmed by re-testsand all of their PCR results were reported negative. No cases of congenital toxoplasmosis were detected during the 3 years in our clinic.Conclusion: The inclusion of toxoplasma in routine screening programme is still controversial and differs between countries. Screening inareas with a high rate of toxoplasma, such as in our country, may be rational. If infection is detected, treatment may be recommendedbecause it may reduce the transmission to the fetus.

Anahtar Kelime:

Türkiye'de Üçüncü Basamak Bir Merkezde Yapılan 9311 Gebede Toksoplazma Taramasının Sonuçları

Öz:

Giriş: Toksoplazma gondi, insanlarda hamilelik sırasında infekte olduğunda fetusa kalıcı sekellere neden olabilecek önemli bir parazittir. Bu parazitin sıklığı ülkeler arasında büyük farklılıklar gösterse de ülkemizde yaygın olduğu bilinmektedir. Bu çalışmanın amacı, Orta Anadolu’daki tersiyer merkez hastaneye başvuran gebe kadınlarda toksoplazmanın seroprevalansını belirlemek ve gebelik sonuçlarını seroprevalansı ile birlikte değerlendirmektir. Materyal ve Metod: Çalışmaya Ocak 2016-Aralık 2018 tarihleri arasında hastaneye başvuran toplam 9311 hasta alındı. Serolojik incelemeden sonra akut infeksiyonu düşündüren olgulara avidite testi yapıldı. Düşük avidite saptananlarda Polimeraz Zincir Reaksiyonu (PCR) yapılması için amniyosentez önerildi. Bulgular: Toksoplazma immünglobulin (Ig) G ve M seropozitiflik sıklığı sırasıyla %20.3 ve %0.28 idi. IgM pozitifliği olan hastaların yaklaşık %27’sinde düşük avidite bulunmuştur ve doğrulama testiyle sadece %15.4’ünde düşük avidite saptanmıştır. Düşük avidite değeri tekrar testlerle doğrulanan 4 hastaya PCR yapıldı ve tüm PCR sonuçları negatif olarak bildirildi. Kliniğimizde 3 yıl boyunca hiçbir hastada konjenital toksoplazmoz olgusu saptanmadı. Sonuç: Rutin tarama programına toksoplazmanın dahil edilmesi halen tartışmalıdır ve ülkeler arasında farklılık göstermektedir. Ülkemizde olduğu gibi yüksek oranda toksoplazma bulunan bölgelerde tarama yapılması rasyonel olabilir. İnfeksiyon tespit edilirse, fetusa geçişi azaltabileceğinden tedavi önerilebilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Centers for Disease Control and Prevention (CDC). Parasites - Toxoplasmosis (Toxoplasma infection) Erişim tarihi: 23 Ağustos 2015. Available from: https://www.cdc.gov/ parasites/toxoplasmosis/epi.html
2. Hunter CA, Sibley LD: Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol 2012;10:766.
3. Welton NJ, Ades AE. A model of toxoplasmosis incidence in the UK: Evidence synthesis and consistency of evidence. JRSS-C Applied Statistics 2005;54:385
4. Gilbert RE, Peckham CS. Congenital toxoplasmosis in the United Kingdom: to screen or not to screen? J Med Screen 2002;9:135-41.
5. Remington JS MR, Thulliez P, Desmonts G. Toxoplasmosis. In: Remington KJ, Wilson CB, Baker CJ (eds). Infectious disease of the fetus and newborn infant. 6th ed. Philadelphia: Elsevier Saunders, 2006:947.
6. Maldonado YA, Read JS. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics 2017;139:e20163860
7. Pappas G, Roussos N, Falagas ME. Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 2009;39:1385-94.
8. Jones JL, Kruszon-Moran D, Rivera HN, Price C, Wilkins PP. Toxoplasma gondii seroprevalence in the United States 2009-2010 and comparison with the past two decades. Am J Trop Med Hyg 2014;90:1135-9.
9. Hohlfeld P, Daffos F, Thulliez P, Aufrant C, Couvreur J, MacAleese J, et al: Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989;115):765-9.
10. Thiebaut R, Leproust S, Chene G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients’ data. Lancet 2007;369:115- 22.
11. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycy-stic ovaries. Am J Obstet Gynecol 1935;29:181- 91.
12. Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can 2018;40:e687-93.
13. Practice bulletin no. 151: Cytomegalovirus, parvovirus B19, varicella zoster, and toxoplasmosis in pregnancy. Obstet and Gynecol 2015;125:1510-25.
14. Gilbert R, Gras L. Effect of timing and type of treatment on the risk of mother to child transmission of Toxoplasma gondii. BJOG 2003;110:112-20.
15. Wallon M, Peyron F, Cornu C, Vinault S, Abrahamowicz M, Kopp CB, et al. Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years. Clin Infect Dis 2013;56(9):1223-31.
16. Koloren Z, Dubey JP. A review of toxoplasmosis in humans and animals in Turkey. Parasitology 2019;147:1-17.
17. Prenatal Care Management Guide, 2014.
18. Ocak S, Zeteroglu S, Ozer C, Dolapcioglu K, Gungoren A. Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in southern Turkey. Scandinavian J Infect Dis 2007;39:231-4.
19. Harma M, Harma M, Gungen N, Demir N. Toxoplasmosis in pregnant women in Sanliurfa, Southeastern Anatolia City, Turkey. J Egypt Soc Parasitol 2004;34:519-25.
20. İnci M, Yağmur G, Aksebzeci T, Kaya E, Yazar S. Kayseri’de kadınlarda Toxoplasma gondii seropozitifliğinin araştırılması. Türkiye Parazitol Derg 2009;33:191-4.
21. Hedman K, Lappalainen M, Seppäiä I, Mäkelä O. Recent primary toxoplasma infection indicated by a low avidity of specific IgG. J Infect Dis 1989;159:736-40.
22. Peyron F, Mc Leod R, Ajzenberg D, Contopoulos-Ioannidis D, Kieffer F, Mandelbrot L, et al. Congenital toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Negl Trop Dis 2017;11:e0005222.
23. Sickinger E, Gay-Andrieu F, Jonas G, Schultess J, Stieler M, Smith D, et al. Performance characteristics of the new ARCHITECT toxo IgG and Toxo IgG avidity assays. Diagn Microbiol Infect Dis 2008;62(3):235-44.
24. Jost C, Touafek F, Fekkar A, Courtin R, Ribeiro M, Mazier D, et al. Utility of Immunoblotting for early diagnosis of toxoplasmosis seroconversion in pregnant women. Clin Vaccine Immunol 2011;18:1908-12.
25. Bobic B, Klun I, Vujanic M, Nikolic A, Ivovic V, Zivkovic T, et al. Comparative evaluation of three commercial Toxoplasma-specific IgG antibody avidity tests and significance in different clinical settings. J Med Microbiol 2009;58:358-64.
26. Beghetto E, Buffolano W, Spadoni A, Del Pezzo M, Di Cristina M, Minenkova O, et al. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. J Clin Microbiol 2003;41(12):5414-8.
27. Villard O, Breit L, Cimon B, Franck J, Fricker-Hidalgo H, Godineau N, et al. Comparison of four commercially available avidity tests for Toxoplasma gondii-specific IgG antibodies. Clin Vaccine Immunol 2013;20:197-204.
28. Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 2012;25:264-96.
29. de Oliveira Azevedo CT, do Brasil PE, Guida L, Lopes Moreira ME. Performance of polymerase chain reaction analysis of the amniotic fluid of pregnant women for diagnosis of congenital toxoplasmosis: A systematic review and meta-analysis. PloS ONE 2016;11:e0149938.
30. Tamma P. Toxoplasmosis. Pediatr Rev 2007;28:470-1.

APA	kocak o, kan o (2020). Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. , 332 - 338. 10.5578/flora.69026
Chicago	kocak ozgur,kan ozgur Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. (2020): 332 - 338. 10.5578/flora.69026
MLA	kocak ozgur,kan ozgur Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. , 2020, ss.332 - 338. 10.5578/flora.69026
AMA	kocak o,kan o Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. . 2020; 332 - 338. 10.5578/flora.69026
Vancouver	kocak o,kan o Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. . 2020; 332 - 338. 10.5578/flora.69026
IEEE	kocak o,kan o "Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey." , ss.332 - 338, 2020. 10.5578/flora.69026
ISNAD	kocak, ozgur - kan, ozgur. "Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey". (2020), 332-338. https://doi.org/10.5578/flora.69026

APA	kocak o, kan o (2020). Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25(3), 332 - 338. 10.5578/flora.69026
Chicago	kocak ozgur,kan ozgur Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25, no.3 (2020): 332 - 338. 10.5578/flora.69026
MLA	kocak ozgur,kan ozgur Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, vol.25, no.3, 2020, ss.332 - 338. 10.5578/flora.69026
AMA	kocak o,kan o Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(3): 332 - 338. 10.5578/flora.69026
Vancouver	kocak o,kan o Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey. Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi. 2020; 25(3): 332 - 338. 10.5578/flora.69026
IEEE	kocak o,kan o "Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey." Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi, 25, ss.332 - 338, 2020. 10.5578/flora.69026
ISNAD	kocak, ozgur - kan, ozgur. "Results of the Toxoplasmosis Screening in 9311 Pregnant Women in a Tertiary Center in Turkey". Flora İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Dergisi 25/3 (2020), 332-338. https://doi.org/10.5578/flora.69026